Human papilloma virus immunoreactive peptides
AssigneeThe United States of America as represented by the Department of Health and Human Services
InventorsSamir Khleif, Jay Berzofsky
Life of this patent
Estimating the term…
Abstract
This invention provides immunogenic peptides from the HPV-18E6 protein that comprise class I restricted T cell epitopes and discloses methods of administering these peptides to individuals, and a method for monitoring or evaluating an immune response to HPV with these peptides.
Claims18
A method of inducing a cytotoxic T lymphocyte response against human papilloma virus 16 (HPV 16) in a patient, the method comprising contacting cytotoxic T cells from a patient with an immunogenic peptide of 20 amino acid residues or less comprising a cross-reactive peptide from the E6 protein of a related HPV strain, HPV 18, that has higher affinity for the HLA-A2.1 molecule than the corresponding epitope from HPV 16 itself, said peptide comprising the sequence X1KLPDLCTEL(SEQ ID NO:1)X2, wherein X1 and X2 are peptides of 0-11 amino acids in length comprising either native or non-native amino acid sequence and returning said cytotoxic T cells to the patient in an amount sufficient to induce a cytotoxic T cell response.
8-12. (canceled)
A vaccine for preventing or treating human papilloma virus 16 (HPV 16) infection that induces a protective or therapeutic immune response, wherein said vaccine comprises a peptide of 20 amino acids or less comprising a cross-reactive peptide from the E6 protein of a related HPV strain, HPV 18, that has higher affinity for the HLA-A2.1 molecule than the corresponding epitope from HPV 16 itself, said peptide comprising the sequence X1KLPDLCTEL(SEQ ID NO:1)X2, wherein X1 and X2 are peptides of 0-11 amino acids in length comprising either native or non-native amino acid sequences and a pharmaceutically acceptable carrier.
16-18. (canceled)
A method for inducing a a cytotoxic T lymphocyte response against human papilloma virus 16 (HPV 16) comprising administering to a subject a composition, which is selected from a group consisting of:
- (i) a peptide of 20 amino acids or less comprising a cross-reactive peptide from the E6 protein of a related HPV strain, HPV 18, that has higher affinity for the HLA-A2.1 molecule than the corresponding epitope from HPV 16 itself, said peptide consisting of the sequence X1KLPDLCTEL(SEQ ID NO:1)X2, wherein X1 and X2 are peptides of 0-11 amino acids in length comprising contiguous HPV 18 E6 amino acid sequences;
- (ii) an antigen presenting cell pulsed with said peptide;
- and
- (iii) a cell sensitized in vitro to said peptide.
Dependencies are inferred from the claim text.